Literature DB >> 17318736

High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1.

C-S Tan1, M J Cardosa.   

Abstract

Human enterovirus 71 has emerged as an important pathogen of children in the Asia Pacific region, and it may be important to consider the development of a vaccine against this virus. Human cord serum was used as a source of neutralizing antibodies to determine whether the N- or C-terminal half of the VP1 capsid protein was more likely to harbour neutralizing determinants. Cord sera from 205 individuals were tested for neutralizing antibodies against human enterovirus 71 in an indirect ELISA against recombinant VP1 antigen as well as the N- and C-terminal portions of VP1 antigen. High-titred human neutralizing antibodies were significantly more reactive with the N-terminal half of VP1 than weak or negative sera. The N-terminal half of human enterovirus 71 is likely to have important neutralizing antibody determinants and should be investigated further in vaccine development efforts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318736     DOI: 10.1007/s00705-007-0941-1

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  17 in total

1.  A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China.

Authors:  Yongjuan Liu; Chong Fu; Suying Wu; Xiong Chen; Yingying Shi; Bingfei Zhou; Lianglu Zhang; Fengfeng Zhang; Zhihao Wang; Yingying Zhang; Chengpeng Fan; Song Han; Jun Yin; Biwen Peng; Wanhong Liu; Xiaohua He
Journal:  Virus Genes       Date:  2014-01-19       Impact factor: 2.332

2.  Adaptive Immune Responses following Senecavirus A Infection in Pigs.

Authors:  Mayara F Maggioli; Steve Lawson; Marcelo de Lima; Lok R Joshi; Tatiane C Faccin; Fernando V Bauermann; Diego G Diel
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

Review 3.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

4.  Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity.

Authors:  Su-Lin Yang; Ying-Ting Chou; Cheng-Nan Wu; Mei-Shang Ho
Journal:  J Virol       Date:  2011-09-07       Impact factor: 5.103

5.  Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates.

Authors:  Si Ying Ho; Shi Qian Chua; Damian G W Foo; Camille Locht; Vincent T Chow; Chit Laa Poh; Sylvie Alonso
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

6.  Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection.

Authors:  Guo-hui Chang; Yan-jun Luo; Xiao-yan Wu; Bing-yin Si; Lei Lin; Qing-yu Zhu
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

7.  Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model.

Authors:  Minetaro Arita; Yasushi Ami; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

8.  Immunization with recombinant enterovirus 71 viral capsid protein 1 fragment stimulated antibody responses in hamsters.

Authors:  Wei-Choong Ch'ng; Eric J Stanbridge; Kum-Thong Wong; Kien-Chai Ong; Khatijah Yusoff; Norazizah Shafee
Journal:  Virol J       Date:  2012-08-09       Impact factor: 4.099

9.  Genetic diversity and C2-like subgenogroup strains of enterovirus 71, Taiwan, 2008.

Authors:  Yuan-Pin Huang; Tsuey-Li Lin; Li-Ching Hsu; Yu-Ju Chen; Yin-Hsin Tseng; Chiu-Chu Hsu; Wen-Bin Fan; Jyh-Yuan Yang; Feng-Yee Chang; Ho-Sheng Wu
Journal:  Virol J       Date:  2010-10-20       Impact factor: 4.099

10.  Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice.

Authors:  Balraj Premanand; Mookkan Prabakaran; Tanja K Kiener; Jimmy Kwang
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.